Business
Aussie biotech Starpharma signs deal to sell COVID nose spray in Britain – Sydney Morning Herald
The Melbourne-based firm’s market value is approaching the billion-dollar mark amid rising investor interest in its COVID-preventative treatment.
Australian biotech Starpharma is taking its COVID-fighting antiviral nasal spray to the world, signing a deal with UK chemist chain LloydsPharmacy to sell the product in Britain as the country emerges from lockdown.
The Melbourne-based company announced a deal on Thursday morning that will see its Viraleze virus-fighting product sold online in the UK starting next week. It will also be stocked in Lloyds 1400-strong pharmacy network.
Chief executive Jackie Fairley declined to comment on the value…
-
Noosa News8 hours agoJessica Alba spotted filming spy thriller on the Gold Coast as cameras roll under iconic bridge
-
Noosa News20 hours agoTallest tower outside CBD approved for construction at 205 metres
-
Noosa News21 hours agoFarmgate Backpackers leads with integrity amid industry challenges
-
General16 hours agoWall St futures bounce, Asia still shaky